Xacduro Now Available for Pneumonia Caused by Acinetobacter

Xacduro^® (sulbactam for injection; durlobactam for injection) is now available for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.

The co-packaged product contains sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor. The safety and efficacy of Xacduro was established in the phase 3 ATTACK trial (ClinicalTrials.gov Identifier: NCT03894046), which compared Xacduro to colistin in patients with documented A. baumannii-calcoaceticus complex infections.

Xacduro is available by prescription through specialty pharmacy distributors as a kit containing a single dose vial of sulbactam 1g and 2 single-dose vials of durlobactam (0.5g in each vial). The product requires reconstitution and further dilution prior to intravenous infusion. The recommended duration of treatment is 7 to 14 days; the duration of therapy is guided by the patient’s clinical status. The dosing regimen should be adjusted based on renal function.

“Xacduro’s pathogen-targeted approach is a significant advancement in the way health care professionals treat Acinetobacter, one of the most serious antibiotic-resistant pathogens known to cause life-threatening pneumonia that is associated with high morbidity and mortality rates,” said Pavel Raifeld, CEO, Innoviva. “The addition of Xacduro to our portfolio of critical care medicines underscores our commitment to this space by providing health care professionals with differentiated therapeutic options to help improve patient outcomes.”